author-photo

Lena Lemke

4

Papers

17

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS).

2021 BioDrugs
Show All
- Source
- Cite
- Save
Citations (0)
AB0208 DO LOW CONCENTRATIONS OF CITRATE IN AN ADALIMUMAB FORMULATION IMPACT THE INCIDENCE AND/OR INTENSITY OF INJECTION SITE PAIN? DATA FROM PHASE I AND III STUDIES ASSESSING THE LOCAL TOLERANCE OF GP2017 (ADALIMUMAB BIOSIMILAR, SDZ-ADL) IN HEALTHY VOLUNTEERS, RHEUMATOID ARTHRITIS, AND PSORIASIS PATIENTS

2021 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (0)
GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods

2019 Expert Opinion on Biological Therapy
Show All
- Source
- Cite
- Save
Citations (14)